What is the Clinical Trials Activity initiative?

The Clinical Trials Activity initiative will invest $614.2 million over 10 years to increase clinical trial activity in Australia.

It incorporates the following Medical Research Future Fund (MRFF) grant opportunities:

Why is the Clinical Trials Activity initiative important?

This initiative is important because it:

  • gives patients across Australia more access to clinical trials
  • shows which treatments and medicines work best for patients
  • provides researchers with more opportunities to work with international colleagues in world-wide trials

What are the goals of the Clinical Trials Activity initiative?

This initiative aims to increase clinical trial activity in Australia, help patients access clinical trials, and enable researchers to bring international trials to Australian patients.

How will we meet these goals?

Our early funding priority areas are:

  • reproductive cancers
  • childhood brain cancer
  • neurological disorders
  • low-survival cancers and diseases

 See the initiative snapshot for details of how we plan to meet these goals.

MRFF snapshot – Clinical Trials Activity

This snapshot shows this initiative at a glance. It includes budgets, early funding priorities and grant timelines, as at November 2019. Researchers and other stakeholders can use it to plan for upcoming opportunities and see how the initiative will be established, expanded and embedded over time.

Who works with us on the Clinical Trials Activity initiative?

The Medical Research Future Fund (MRFF) funds the initiative.

Our Health and Medical Research Office oversees this and other MRFF initiatives.

The National Health and Medical Research Council (NHMRC) administers this initiative.

Apply for funding

We will list grants on GrantConnect when they open. If you want GrantConnect to notify you about future MRFF grants:

  • register with them
  • enter ‘MRFF’ in the keyword section of your GrantConnect profile

Status

Upcoming grants

There are currently no upcoming grants. 

Open grant rounds

Four Rare Cancers, Rare Diseases and Unmet Need grant opportunities opened on 15 November 2019 and will close on 5 February 2020, for research into:

International Clinical Trial Collaboration is a perpetually open grant opportunity with 3 scheduled closing dates each year.

Grants being assessed

The most recent grant opportunity is currently being assessed.

Grants awarded

We have funded the following projects under this initiative, as at 30 September 2019.

Funded Institution

Project Name

Chief Investigator

Total Funding

Murdoch Children’s Research Institute

A randomised control trial of positive end-expiratory pressure levels during resuscitation of preterm infants at birth (The POLAR Trial)

Associate Professor David Tingay

$1,387,654

The George Institute for Global Health

The SAHaRA Trial: Understanding the best red cell transfusion practice in patients with intracranial
bleeding from a ruptured aneurysm

Associate Professor Anthony Delaney

$902,752

University of Western Australia

The Early valve replacement in severe ASYmptomatic aortic stenosis (EASY AS) trial

Professor Graham Hillis

$1,827,443

Macquarie University

The Australian-multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention (AU-ARROW) study

Professor Ralph Martins

$3,115,063

The University of Newcastle

Sunrise Australia - A randomised clinical trial of single use negative pressure dressing for reduction in surgical site infection following emergency laparotomy.

Dr Peter Pockney

$782,256

La Trobe University

Prospective, multicentre trial evaluating FET-PET in high grade glioma

Professor Andrew Scott

$1,564,188

Monash University

A collaborative study of the Interfant network (Australian sites): the feasibility, safety and efficacy of the addition of Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged Acute Lymphoblastic Leukaemia (The Blin-fant Study)

Doctor Rishi Kotecha

$314,772

Monash University

A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukaemia (AML)

Associate Professor Andrew Wei

$1,507,785

Monash University

CAST – A Randomised Phase 3 Trial of Cyclophosphamide after Sibling Allogeneic Haematopoietic Stem Cell Transplant

Associate Professor David Curtis

$1,570,198

Monash University

The BLENDER Trial – Blend to Limit Oxygen in ECMO: A randomised Controlled Registry Trial

Professor David Pilcher

$753,355

Monash University

The DIAAMOND study: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset

Associate Professor Erica Wood

$1,750,726

Murdoch Children’s Research Institute

The efficacy of rehabilitation for hereditary ataxias- a randomised controlled trial

Professor Martin Delatycki

$1,227,418

The University of Adelaide

Treatment of Severe Early Onset Intrahepatic Cholestasis of Pregnancy

Professor William Hague

$1,191,769

The University of Queensland

A platform clinical trial approach to the management of Mycobacterium abscessus complex (MABSC)

Professor Claire Wainwright

$2,091,178

The University of Queensland

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies

Professor Maher Gandhi

$1,642,389

The University of Queensland

Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer

Professor Janet Hardy

$1,363,040

The University of Western Australia

BEAT-CF: Bayesian Evidence-Adaptive Trial to optimise management of Cystic Fibrosis

Associate Professor Thomas Snelling

$3,545,905

University of Melbourne

SpeechAtax: A rater-blinded randomised controlled trial of intensive home-based speech treatment for ataxia

Associate Professor Adam Vogel

$498,627

University of Melbourne

STOP-MSU: Stopping haemorrhage with Tranexamic acid cOmmenced Prehospital in a Mobile Stroke Unit

Professor Stephen Davis

$1,285,820

University of New South Wales

CRISTAL: Cluster Randomised Trial of Apsirin versus Low molecular weight heparin for venous thromboembolism prophylaxis in joint replacement surgery, a registry-nested study

Professor Ian Harris

$934,848

University of New South Wales

Immunotherapy Targeting of Cytomegalovirus antigens in Glioblastoma: INTERROGATE-GBM

Associate Professor Kerrie McDonald

$1,446,002

University of Sydney

A randomised controlled trial, of N-Acetyl Cysteine, for premanifest Huntingtin gene expansion carriers (NAC-preHD)

Associate Professor Clement Loy

$1,905,227

University of Sydney

The BEST-Fluids study: Better Evidence for Selecting Transplant Fluids

Professor Steven Chadban

$1,117,150

Murdoch Childrens Research Institute
(Australian National University)

A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics.

Professor Anne-Louise Ponsonby

$887,072

Deakin University

The Candesartan Adjunctive Bipolar Depression Trial - CADET

Professor Michael Berk

$2,428,397

La Trobe University

Improving muscle strength in young people with Prader-Willi syndrome

Professor Nora Shields

$874,179

Menzies School of Health Research

Improving outcomes of children and young adults with primary ciliary dyskinesia (PCD): a multi-centre, double-blind, double-dummy, 2x2 factorial, randomised controlled trial (RCT)

Professor Anne Chang

$2,375,118

Monash University

COZMOS: Phase I/Ib trial of combined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tumours

Doctor Jordan Hansford

$125,355

Monash University

Erythropoietin alfa to prevent mortality and reduce severe disability in critically ill trauma patients: a multicentre, stratified, double blind, placebo randomised controlled trial (the EPO-TRAUMA trial)

Associate Professor Craig French

$3,509,303

Monash University

Evaluating the effectiveness and safety of sodium selenate as a disease modifying treatment for patients with behavioural variant Frontotemporal Dementia (bvFTD)

Professor Terence O'Brien

$1,604,184

Monash University

FaR-RMS: Frontline And Relapse study in RhabdoMyoSarcoma

Doctor Martin Campbell

$1,353,514

Monash University

Novel Veneticlax Combinations to Improve Outcomes in  Unfit Older Patients with Acute Myeloid Leukaemia

Associate Professor Andrew Wei

$1,380,298

Monash University

SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, Molecularly-Targeted CHK1/2i Therapy, in Combination with Cyclophosphamide or Gemcitabine for Children and Adolescents with Refractory or Recurrent Medulloblastoma Brain Tumours

Associate Professor Nicholas Gottardo

$226,284

The University of Queensland

A Randomised Phase II Trial of Adjuvant Avelumab in Patients with Early Stage Merkel Cell Carcinoma

Doctor Wen Xu

$1,632,096

The University of Queensland

An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma

Professor Maher Gandhi

$3,596,967

The University of Queensland

The TEACH-PD study: a targeted education approach to improve peritoneal dialysis outcomes

Professor David Johnson

$2,383,207

University of Canberra

Evaluation of a bush medicine-based treatment for scabies in Australian Aboriginal children

Doctor Jackson Thomas

$1,294,542

University of Melbourne

The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma

Doctor Constantine Tam

$2,005,391

University of New South Wales

Aldosterone blockade for health improvement evaluation in end-stage renal disease (ACHIEVE) study

Associate Professor Martin Gallagher

$2,850,898

University of New South Wales

BEAT-Calci (Better Evidence And Translation in Calciphylaxis)

Associate Professor Meg Jardine

$2,201,944

University of New South Wales

Does Withholding Enteral feeds Around blood Transfusion reduce the incidence of necrotising enterocolitis (NEC) in very preterm infants? The international WHEAT Study

Professor Kei Lui

$1,606,826

University of New South Wales

MEMOIR: A multi-site placebo-controlled trial of memantine and graded motor imagery for complex regional pain syndrome

Associate Professor James McAuley

$922,314

University of Sydney

ALS Trials Australia (ALSTA) - to develop precision medicine

Professor Matthew Kiernan

$1,704,432

University of Sydney

MAGMA: Multi-Arm GlioblastoMa Australasia Trial

Doctor Craig Gedye

$1,273,632

University of Sydney

NAVMAN TRIAL: A multi-centre, dynamic, waitlist randomised controlled trial of patient navigators in children with chronic kidney disease

Associate Professor Germaine Wong

$1,093,681

University of Sydney

PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma.

Associate Professor Judith Trotman

$787,069

University of Sydney

PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma

Doctor Hao-Wen Sim

$1,391,472

La Trobe University / Olivia Newton-John Cancer Research

A Basket Study of Low Survival Cancers Treated with EGFR-ADCs

Associate Professor Hui Gan

$1,658,626

Monash University

Brain Oxygen Neuromonitoring In Australia And New Zealand Assessment (BONANZA) Trial

Associate Professor Andrew Udy

$1,084,852

Monash University

Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study

Professor Andrew Spencer

$1,682,836

Monash University

Improving survival in myelofibrosis

Professor Andrew Perkins,

$1,733,327

University of Melbourne

Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC)

Doctor Shahneen Sandhu

$1,812,005

University of Sydney

mFOLFIRINOX and STEreotactic body radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG)

Associate Professor Andrew Kneebone

$1,512,808

Australian Clinical Trial Alliance

Strengthening the capacity, efficiency and effectiveness of Clinical trials networks through the Australian Clinical Trial Alliance

Not Applicable

$5,000,000

Total

 

$87,718,196

Related information

See a list of all MRFF grant recipients.

Contact

For more information, see the NHRMC's Investigator Grants page or contact them.

Medical Research Future Fund (MRFF) contact

Contact for more information about the Medical Research Future Fund (MRFF), or to provide feedback on the MRFF website.

General enquiries:
MRFF [at] health.gov.au
MRFF website feedback:
HMRO [at] health.gov.au

View contact

National Health and Medical Research Council (NHMRC)

The National Health and Medical Research Council (NHMRC) funds high quality health and medical research to build research capability, support researchers, encourage the translation of research into better health outcomes and promote the highest ethical standards for health and medical research.

help [at] nhmrc.gov.au

View contact

Last updated: 
24 December 2019